REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
18/04/2026
Voltar para busca
Dado oficial do USPTO
SEQIRUS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
47
Atualização mais recente
19/04/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 44
Data de depósito
17/08/2015
Data de registro
18/04/2017
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
16/04/2024
Última transação
19/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
705
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
3
Tipo de titular
99
Localização do titular
Berkshire, GB
Examinador
SNABB, SANDRA MARIE
Unidade examinadora
N20
Descrição da marca
The mark consists of stylized wording "SEQIRUS" with a curved line over the letter "S" under another curved line which spans from over the letter "S" to over the letter "E".
Titulares e representantes
Titulares
Seqirus UK Limited
Seqirus UK Limited
Representantes
Nancy Sabarra Fross Zelnick Lehrman & Zissu, P.C.
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical and biological reagents for scientific and non-medical purposes; cell cultures and media for laboratoryscientific and research use; test kits for scientific and non-medical laboratory use for anti-body screeningblood grouping or detection of specific blood cellsantigens and immunoglobulin subtypes; chemical preparations for scientific and industrial purposes; diagnostic and testing agents for scientific and non-medical purposes; Chemical and biological reagents for non-medical purposes; chemical and biological reagents for industrial use for anti-body screeningblood groupingfor the typing and detection of specific blood cellsdetermining the presence of antigens on blood cellsthe detection of relevant complement compounds and immunoglobulin subtypes; chemical test kits for the detection of specific blood cellsdetermining the presence of antigens on blood cellsthe detection of relevant complement compounds and immunoglobulin subtypes for laboratory or research use; chemical preparations for industrial use for anti-body screeningblood groupingthe typing and detection of specific blood cells
Classe 5
Pharmaceutical preparations and substances for the treatment and prevention of blood disordersbleeding disordersdiseases caused by bacteria and viruses; vaccines; blood productsimmunoglobulins for medical or clinical use; medicated serums for the treatment of influenza; anti-virals; influenza vaccines; adjuvants and antigens for medical purposes; blood productsblood plasmareagent blood cells; products derived from blood and products derived from recombinant DNA technologyimmunoglobulinshuman albuminblood clotting factorsplasma volume expandersblood proteins for therapeutic use; serumsanti-venoms; medicated serums for the treatment of blood disorders and bleeding disorders; test kitsinvitro diagnostic reagent test kits for use in detecting cell mediated immune response; pharmaceutical preparations and substancesRheysys Factor D Antigen reagents for the detection of specific antigens or in blood typing; pharmaceutical preparationsreagent red blood cells used to detect antibodies and Immunoglobulin subtypes; pharmaceutical preparationstherapeutic monoclonal and polyclonal antibodies and antibodies for use in the treatment of infectious diseases ; pharmaceutical preparationsreagents for medical and clinical use for the typing and detection of specific blood cellsthe detection of relevant compliment components and immunoglobulin subtypes
Classe 44
Medical services; medical information services; health care services; health care information servicesinternet-based health care information services; providing medical information concerning blood products; providing medical information concerning vaccinesanti-venoms and immunohematology productsdiagnostic reagents; patient support servicesproviding an Internet-based database of patient medical informationwhere patients can enquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community
Publicações
Histórico de despachos e eventos da marca no USPTO.
47 publicações encontradas
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
16/04/2024
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
16/04/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
16/04/2024
E815
TEAS SECTION 8 & 15 RECEIVED
18/10/2023
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
18/04/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
25/11/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
25/11/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
18/12/2018
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
18/12/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
18/04/2017
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
13/03/2017
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
13/03/2017
IUCN
NOTICE OF ALLOWANCE CANCELLED
06/03/2017
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
06/03/2017
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
07/02/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
13/12/2016
PUBO
PUBLISHED FOR OPPOSITION
13/12/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
23/11/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
10/11/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/11/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
31/10/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
31/10/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
24/10/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
20/09/2016
GNRT
NON-FINAL ACTION E-MAILED
20/09/2016
CNRT
NON-FINAL ACTION WRITTEN
20/09/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/09/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/09/2016
ALIE
ASSIGNED TO LIE
25/08/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
18/08/2016
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/07/2016
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/07/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
24/06/2016
GNRT
NON-FINAL ACTION E-MAILED
24/06/2016
CNRT
NON-FINAL ACTION WRITTEN
24/06/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/06/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/06/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/06/2016
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/06/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/12/2015
GNRT
NON-FINAL ACTION E-MAILED
03/12/2015
CNRT
NON-FINAL ACTION WRITTEN
03/12/2015
DOCK
ASSIGNED TO EXAMINER
01/12/2015
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
21/08/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
20/08/2015
NWAP
NEW APPLICATION ENTERED
20/08/2015
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SEQIRUS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.